Nontuberculous Mycobacterial Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Nontuberculous Mycobacterial Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Nontuberculous Mycobacterial, historical and forecasted epidemiology as well as the Nontuberculous Mycobacterial market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock detailed insights into the Nontuberculous Mycobacterial Market by downloading the comprehensive report from DelveInsight @ Nontuberculous Mycobacterial Treatment Market Size- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Nontuberculous Mycobacterial Market Report
• In December 2025, Insmed Incorporated announced a study is to evaluate the efficacy of ALIS (amikacin liposome inhalation suspension) + background regimen (azithromycin [AZI] + ethambutol [ETH]) compared to the ELC (empty liposome control) + background regimen on participant-reported respiratory symptoms at Month 13.
• According to DelveInsight's epidemiology model, the total Nontuberculous Mycobacterial Infections diagnosed prevalent cases were approximately 108 thousand cases in the US in 2023 which are expected to increase during the forecast period (2024-2034) due to several factors. An aging population and rising rates of chronic lung diseases like COPD and bronchiectasis contribute significantly. Enhanced awareness and improved diagnostic tools have led to more frequent identification and reporting of these infections.
• In the US, NTM Infections exhibit a female preponderance compared to males in 2023. Of the total Nontuberculous Mycobacterial Infections diagnosed prevalent cases, femaes accounted for nearly 68%, while males accounted for approximately 32%. The prevalence of NTM infections is higher in females due to a combination of biological, behavioral, and environmental factors. Females are more likely to have certain chronic lung diseases, such as bronchiectasis, which predispose them to NTM infections. Hormonal differences and immune system variations may also play a role.
• In 2023, among the species-specific cases, M. avium accounted for the highest Nontuberculous Mycobacterial Infections diagnosed prevalent cases in the US accounting for nearly 76 thousand cases followed by M. abscessus with nearly 14 thousand cases, and others (M. kansasii, M. xenopi, etc.) with approximately 18 thousand cases. The diagnosed prevalent cases of NTM infections caused by M. avium species are higher in the United States due to the widespread presence of M. avium in the environment, including soil, water, and household plumbing systems, which increases the likelihood of exposure.
• In the US, there were approximately 86 thousand Nontuberculous Mycobacterial Infections diagnosed prevalent cases among pulmonary type and nearly 22 thousand cases among extrapulmonary type in 2023.
• In the US, the highest number of Nontuberculous Mycobacterial Infections diagnosed cases were moderate followed by mild and severe cases with approximately 58 thousand, 36 thousand, and 13 thousand cases respectively in 2023.
• The leading Nontuberculous Mycobacterial Companies such as Insmed Incorporated, RedHill Biopharma, Novoteris, Savara Inc., Beyond Air, and others.
• Promising Nontuberculous Mycobacterial Therapies such as SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others.

Gain a competitive edge in the Nontuberculous Mycobacterial Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Nontuberculous Mycobacterial Treatment Drugs- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Nontuberculous Mycobacterial Epidemiology Segmentation
• NTM Infections Segmentation By Disease Type
• NTM Infections Segmentation By Causative Species
• NTM Infections Segmentation By Age Group
• NTM Infections Segmentation By Geography

Discover the latest breakthroughs in the Nontuberculous Mycobacterial Market Report-Download the full report now! @ Nontuberculous Mycobacterial Prevalence- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Nontuberculous Mycobacterial Infections Marketed Drugs
ARIKAYCE (amikacin liposome inhalation suspension): Insmed
ARIKAYCE is the first FDA-approved therapy indicated for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE liposomal technology enables the delivery of amikacin directly to the lungs, where lung macrophages take it up, targeting the site of infection. This approach prolongs the release of amikacin in the lungs while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira Nebulizer System manufactured by PARI Pharma GmbH.

Nontuberculous Mycobacterial Infections Emerging Drugs
• Epetraborole: AN2 Therapeutics
Epetraborole (EBO), developed by AN2 Therapeutics, is a novel, once-daily, orally administered investigational treatment for patients with chronic NTM lung disease. Epetraborole is a boron-containing small molecule inhibitor of bacterial leucyl-tRNA synthetase, or LeuRS, an enzyme that catalyzes the attachment of leucine to transfer RNA, or tRNA, molecules, an essential step in protein synthesis. Epetraborole forms a complex with a tRNALEU molecule, trapping the terminal ribonucleotide of tRNALEU in the editing site of the enzyme, which prevents the synthetic site from attaching leucine to tRNALEU thus shutting down tRNA leucylation and leading to a block in protein synthesis.

• MNKD-101 (Clofazimine Inhalation Suspension): Mannkind Corporation
MNKD-101, a nebulized formulation of clofazimine, is being developed for the treatment of severe chronic and recurrent pulmonary infections, including NTM lung disease. An orally inhaled formulation of clofazimine is anticipated to offer several clinical advantages over the current solid oral dosage form of this drug. MNKD-101 has been designated as both an orphan drug and a qualified infectious disease product by the US FDA for the treatment of pulmonary NTM infections. Mannkind is also assessing the feasibility of developing a dry-powder formulation of clofazimine using Mannkind's technosphere formulation technology. MNKD-101 is designated with fast-track designation by the US FDA for the treatment of NTM lung infections.

• SPR720 (Fobrepodacin): Spero Therapeutics
SPR720, developed by Spero Therapeutics, is a broad-spectrum oral antibiotic designed to treat NTM pulmonary disease. SPR720 employs a novel mechanism and has no known cross-resistance with marketed antibiotics. SPR720 has demonstrated a broad spectrum of activity in preclinical studies against the most common organisms causing NTM infections, including M. avium complex, or MAC, M. kansasii, and M. abscessus. SPR720 is applicable to both nonrefractory and refractory patients.

Nontuberculous Mycobacterial Drugs Market
Current standard therapy for the most common NTM infection, MAC, involves a three-drug regimen taken for approximately 18 months. However, the rates of culture conversion with this approach are only 45-70%, and relapse or reinfection rates can be as high as 60%. EffectiveNontuberculous Mycobacterial Infections treatment requires a holistic, patient-centered approach, with close monitoring for drug side effects and adherence.

Discover key developments and opportunities in the Nontuberculous Mycobacterial Market. Click here to learn more from DelveInsight's latest report @ Nontuberculous Mycobacterial Therapeutics Market Size- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Nontuberculous Mycobacterial Market Outlook
Nontuberculous Mycobacterial Infections treatment is challenging and requires prolonged, multidrug regimens that are often tailored to the specific NTM species and the site of infection. The management of these infections is complicated by the intrinsic resistance of many NTM species to standard antibiotics, necessitating the use of specialized and often costly medications. Consequently, NTM infections represent a significant and growing market within the pharmaceutical and healthcare industries, with ongoing research efforts focused on developing more effective diagnostic tools and novel therapeutics to improve patient outcomes.

Nontuberculous Mycobacterial Companies
Insmed Incorporated, RedHill Biopharma, Novoteris, Savara Inc., Beyond Air, and others.

Download DelveInsight's Nontuberculous Mycobacterial Market report today and stay ahead in this rapidly evolving field. @ Nontuberculous Mycobacterial Ongoing Clinical Trials- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Nontuberculous Mycobacterial Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Nontuberculous Mycobacterial Companies- Insmed Incorporated, RedHill Biopharma, Novoteris, Savara Inc., Beyond Air, and others.
• Nontuberculous Mycobacterial Therapies- SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others.
• Nontuberculous Mycobacterial Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Nontuberculous Mycobacterial Unmet Needs, KOL's views, Analyst's views, Nontuberculous Mycobacterial Market Access and Reimbursement

Download the report to understand which factors are driving Nontuberculous Mycobacterial Market Trends @ Nontuberculous Mycobacterial Market Trends- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Nontuberculous Mycobacterial Market Report Introduction
2. Executive Summary for Nontuberculous Mycobacterial
3. SWOT analysis of Nontuberculous Mycobacterial
4. Nontuberculous Mycobacterial Patient Share (%) Overview at a Glance
5. Nontuberculous Mycobacterial Market Overview at a Glance
6. Nontuberculous Mycobacterial Background and Overview
7. Nontuberculous Mycobacterial Epidemiology and Patient Population
8. Country-Specific Patient Population of Nontuberculous Mycobacterial
9. Nontuberculous Mycobacterial Current Treatment and Medical Practices
10. Nontuberculous Mycobacterial Unmet Needs
11. Nontuberculous Mycobacterial Emerging Therapies
12. Nontuberculous Mycobacterial Market Outlook
13. Country-Wise Nontuberculous Mycobacterial Market Analysis
14. Nontuberculous Mycobacterial Market Access and Reimbursement of Therapies
15. Nontuberculous Mycobacterial Market Drivers
16. Nontuberculous Mycobacterial Market Barriers
17. Nontuberculous Mycobacterial Appendix
18. Nontuberculous Mycobacterial Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.